As Pfizer’s antiviral use decreases, 70M Paxlovid packs could be left over

Pfizer's Paxlovid beat Merck's COVID-19 antiviral treatment in sales in May, but the boom in demand is slowing down as less than half of Pfizer's production capacity has been sold, according to data surveillance company Airfinity. 

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive